CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Efficacy of anti-TNF therapy for the treatment of patients with moderate-to-severe inflammatory bowel disease; A first Iranian report
Authors
S. Alatab
A. Anoshiravani
+11 more
S.M. Darehranj
N.E. Daryani
H. Fakheri
M. Malekzadeh
R. Malekzadeh
F. Mansour-Ghanaei
A. Mousavi
A. Sadeghi
A. Sima
H. Vahedi
M.J. Zahedi
Publication date
1 January 2020
Publisher
Abstract
BACKGROUND The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-to-severe inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of anti-TNF therapy at the national level. METHODS IBD patients aged 15 > years who received Infliximab and/or CinnoRA® between 2013 to July 2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy of therapy was defined as time to drug discontinuation or need for IBD-related surgery. The safety was assessed based on patient�s reported adverse events. RESULTS We included 315 patients. The mean age of patients was 37.2 years and 62.2 of them developed the disease before age 30 years. Involvement of masculoskeletal system was reported in 7.3 of patients. Partial and complete response to Anti-TNF therapy was seen in 67 of patients. About 16 of patients did not respond to induction therapy and 16.9 of patients lost their response to Anti-TNF during one year. No serious adverse events, serious opportunistic infection, tuberculosis and malignancies reported by patients. Two patients reported pneumonia. CONCLUSION This study for the first time in our country, provides the evidences for efficacy of anti-TNF therapy in moderate to severe IBD patients. © 2020 The Author(s)
Similar works
Full text
Available Versions
Simorgh Research Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kmu.ac.ir:37937
Last time updated on 14/10/2021
Simorgh Research Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kmu.ac.ir:33418
Last time updated on 08/04/2021